On July 2, 2025, the FDA granted accelerated approval to linvoseltamab (Lynozyfic), a BCMA-targeting bispecific antibody, for adults with heavily pretreated relapsed/refractory multiple myeloma, after trials showed a 70% response rate. Also on July 2, 2025, the FDA approved sunvozertinib (Zegfrovy) as the first targeted oral therapy for advanced NSCLC with EGFR exon 20 insertion…
Read more
